Global Health (MEDANTA) investor relations material

Executive summary

• Q1 FY 2027 achieved 26% year-over-year revenue growth, driven by strong patient volumes, improved realizations, and robust operational execution.

• Highest ever quarterly total income of INR 13,262 million, with EBITDA (excluding Noida) up 24% year-over-year and margins at 25.8%.

• PAT was INR 1,573 million, slightly lower than last year due to a one-time exceptional income in Q1 FY 2026.

• 72 new beds added in Q1 FY 2027, with significant expansion in Noida and Lucknow.

• Strategic focus remains on clinical excellence, expanding advanced care access, and disciplined execution across the network.

Financial highlights

• Consolidated income for Q1 FY 2027 was INR 13,262 million, up 26% year-on-year; EBITDA (including Noida) reached INR 3,153 million, up 23% year-on-year, with margins at 23.8%.

• Profit after tax was INR 1,573 million, with margins at 11.9%, slightly lower due to a prior year exceptional gain.

• ARPOB grew 5.5% year-on-year to INR 70,244; ARPP stable at INR 201,891.

• OPD pharmacy revenue up 51% year-on-year to INR 609 million.

• International patient revenue grew 23% year-on-year to INR 782 million.

Outlook and guidance

• Expansion pipeline includes nearly 3,350 additional beds, with major projects in Guwahati, Mumbai, Varanasi, and Delhi.

• Capex of INR 48,500 million planned over the next five years, funded by internal accruals and debt.

• Noida is expected to achieve EBITDA breakeven earlier than previously anticipated.

• Continued focus on scaling clinical talent, technology investments, and operational efficiency.